Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8236962 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(6 years from now) | |
US9840492 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(11 years from now) | |
US10414751 | MYCOVIA PHARMS | Antifungal compounds and processes for making |
Mar, 2036
(11 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8754227 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
Apr, 2031
(6 years from now) | |
US11247981 | MYCOVIA PHARMS | Metalloenzyme inhibitor compounds |
May, 2033
(9 years from now) |
Vivjoa is owned by Mycovia Pharms.
Vivjoa contains Oteseconazole.
Vivjoa has a total of 5 drug patents out of which 0 drug patents have expired.
Vivjoa was authorised for market use on 26 April, 2022.
Vivjoa is available in capsule;oral dosage forms.
Vivjoa can be used as vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential.
Drug patent challenges can be filed against Vivjoa from 27 April, 2031.
The generics of Vivjoa are possible to be released after 17 March, 2036.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Apr 26, 2027 |
Generating Antibiotic Incentives Now(GAIN) | Apr 26, 2032 |
Drugs and Companies using OTESECONAZOLE ingredient
NCE-1 date: 27 April, 2031
Market Authorisation Date: 26 April, 2022
Treatment: Vivjoa is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (rvvc) in females with a history of rvvc who are not of reproductive potential
Dosage: CAPSULE;ORAL